Titan Pharmaceuticals (NASDAQ: TTNP) is one of 106 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its competitors? We will compare Titan Pharmaceuticals to similar companies based on the strength of its profitability, dividends, earnings, institutional ownership, risk, analyst recommendations and valuation.
Valuation and Earnings
This table compares Titan Pharmaceuticals and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Titan Pharmaceuticals||$220,000.00||-$14.30 million||-0.60|
|Titan Pharmaceuticals Competitors||$1.02 billion||$93.10 million||-5.16|
Risk and Volatility
Titan Pharmaceuticals has a beta of -0.13, meaning that its share price is 113% less volatile than the S&P 500. Comparatively, Titan Pharmaceuticals’ competitors have a beta of 1.64, meaning that their average share price is 64% more volatile than the S&P 500.
This table compares Titan Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Titan Pharmaceuticals Competitors||-8,318.61%||-76.36%||-24.32%|
Insider & Institutional Ownership
12.2% of Titan Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 19.5% of Titan Pharmaceuticals shares are owned by insiders. Comparatively, 16.3% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This is a breakdown of recent ratings and recommmendations for Titan Pharmaceuticals and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Titan Pharmaceuticals Competitors||638||2212||5379||218||2.61|
Titan Pharmaceuticals presently has a consensus target price of $2.00, indicating a potential upside of 376.19%. As a group, “Biological products, except diagnostic” companies have a potential upside of 32.20%. Given Titan Pharmaceuticals’ higher probable upside, equities analysts clearly believe Titan Pharmaceuticals is more favorable than its competitors.
Titan Pharmaceuticals competitors beat Titan Pharmaceuticals on 9 of the 13 factors compared.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. The company has a collaboration with Nevada Center for Behavioral Health to evaluate a medication-assisted treatment program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients. Titan Pharmaceuticals, Inc. was founded in 1992 and is based in South San Francisco, California.
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.